A Hidden Vulnerability: How Tariffs Threaten the Implant Supply Chain
In our first installment of this series, we outlined how the Trump administration’s proposed tariffs on imported medical products could significantly disrupt hospital finances. While the entire healthcare system may feel the pinch, few areas are as vulnerable as the implant supply chain—a long-standing pain point for hospitals due to its high costs, lack of transparency, and limited leverage with vendors.
Now, with new tariffs looming over medical device imports, this fragile procurement category may become even harder to manage.
The Nature of Bill-Only: High Cost, Low Control
Bill-Only items—such as surgical implants and specialty devices—are typically provided by vendor representatives and billed to hospitals only after use. Because these products are often outside of traditional purchasing contracts, pricing is set by the vendor, not negotiated in advance. Hospitals have little recourse to dispute pricing or negotiate alternatives once the device is implanted.
As Becker’s Hospital Review explains, many Bill-Only purchases are excluded from GPO-negotiated pricing, which creates significant variation in cost and minimal visibility into markup or reimbursement rates. Read more here.
This lack of predictability already makes Bill-Only a headache for supply chain and finance teams—and tariffs may turn it into a full-blown crisis.
Tariffs Could Inflate Device Costs Even Further
The U.S. is heavily reliant on imported surgical instruments and implants, especially from countries like China, Canada, and Mexico—all of which are directly targeted by recent tariff proposals. As reported in a March 2025 Becker’s article:
- • 82% of surveyed healthcare executives predict a 15% increase in hospital costs tied to tariffs on imports.
- • 81% of medical equipment manufacturers expect longer lead times and higher costs, driven by increased production expenses and import restrictions.
Because most Bill-Only items are not purchased in bulk or under long-term agreements, hospitals will feel the impact of price increases immediately. Vendors are likely to pass tariff-related costs along in full—and with limited contracts in place, hospitals have few ways to push back.
To make matters worse, hospitals often have no visibility into devices arriving onsite until they’re already used. Pricing details aren’t available until after the fact—when the vendor submits a request for payment—leaving hospitals exposed to surprise cost increases without any opportunity to proactively respond.
Smaller Hospitals May Be Disproportionately Affected
Larger health systems may be able to leverage relationships, consolidate purchasing, or use contract negotiation power to offset some of these costs. But smaller facilities—particularly rural hospitals—are at a disadvantage.
These organizations often lack internal resources to track pricing trends or enforce compliance with pricing policies. They also may be less prioritized by vendors during times of equipment shortages or shipping delays.
With 81% of manufacturers forecasting supply shortages and longer delivery windows, smaller hospitals could struggle to source critical Bill-Only devices altogether—potentially leading to delayed or canceled surgeries.
Reimbursement Gaps and Margin Compression
Another major challenge: tariffs are unlikely to be accompanied by increased reimbursement. Medicare, Medicaid, and private insurers set reimbursement rates based on historical cost structures—and those rates don’t automatically adjust when input costs rise.
This means hospitals may be forced to absorb higher costs for implants without additional reimbursement, shrinking already thin margins. According to Black Book’s survey, 90% of finance leaders expect to pass increased costs on to payers and patients, but that shift may not cover the full shortfall.
The Patient Cost Equation
As tariffs push device prices higher, some hospitals may increase out-of-pocket charges to cover the difference. This could lead to higher co-pays or deductibles for patients undergoing procedures involving high-cost implants — such as joint replacements, cardiovascular surgeries, or neurosurgical interventions.
Delayed care is another potential side effect. If hospitals cannot secure necessary devices in a timely or cost-effective way, elective procedures may be postponed, further disrupting patient access and satisfaction.
A Call for Transparency and Automation
If nothing else, this moment should serve as a catalyst for hospitals to take a closer look at how they manage Bill-Only processes. With tariff volatility on the horizon, organizations will need better tools to:
- • Track and compare Bill-Only costs across cases, vendors, and facilities
- • Automate approval workflows and flag pricing anomalies in real-time
- • Capture detailed device usage data for reimbursement support and audit readiness
- • Engage in proactive vendor discussions to mitigate pricing surges
Solutions like Casechek’s Bill-Only management platform are helping health systems gain visibility, control, and negotiating power in this often-overlooked category—helping offset broader market volatility.
Bill-Onlys have always presented a challenge for hospitals. But with tariffs threatening to inflate device costs and disrupt supply chains, it’s no longer just a cost management issue—it’s a strategic imperative. While the instinctive response may be to “freeze expenses”, the unfortunate truth is that even if hospitals stick to their current approved products, there will be volatility in those costs. Whether medical device vendors will pass on their increased costs through increased pricing, additional fees or aggressive contract negotiation, remains to be seen.
Regardless, hospitals that invest now in better data, vendor accountability, and Bill-Only processes will be best positioned to ride out the next wave of financial turbulence—and continue delivering high-quality care, no matter what policy shifts lie ahead.
"*" indicates required fields